Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Nicolet Advisory Services LLC

Nicolet Advisory Services LLC grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 703 shares of the pharmaceutical company’s stock after purchasing an additional 62 shares during the quarter. Nicolet Advisory Services LLC’s holdings in Vertex Pharmaceuticals were worth $288,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Dunhill Financial LLC lifted its stake in Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 24 shares during the last quarter. Brown Lisle Cummings Inc. purchased a new stake in Vertex Pharmaceuticals in the 4th quarter valued at $30,000. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth $33,000. Sugar Maple Asset Management LLC purchased a new position in Vertex Pharmaceuticals during the 4th quarter worth $35,000. Finally, Golden State Wealth Management LLC acquired a new position in Vertex Pharmaceuticals in the fourth quarter valued at $37,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total transaction of $111,034.64. Following the transaction, the executive vice president now owns 67,695 shares of the company’s stock, valued at $30,805,286.70. This represents a 0.36 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the sale, the executive vice president now directly owns 26,512 shares of the company’s stock, valued at approximately $13,256,000. This represents a 10.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,315 shares of company stock valued at $2,121,012 in the last ninety days. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $474.62 on Friday. The stock’s 50 day moving average price is $481.54 and its 200 day moving average price is $463.85. The firm has a market cap of $121.88 billion, a P/E ratio of -215.74, a PEG ratio of 2.11 and a beta of 0.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on VRTX shares. Canaccord Genuity Group raised Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and raised their price target for the stock from $408.00 to $424.00 in a report on Tuesday, February 11th. Morgan Stanley boosted their target price on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an “equal weight” rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. decreased their price target on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a report on Monday, December 23rd. Truist Financial boosted their price objective on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Finally, Royal Bank of Canada raised their target price on shares of Vertex Pharmaceuticals from $408.00 to $420.00 and gave the stock a “sector perform” rating in a research note on Tuesday. Ten investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $509.17.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.